[1]
Muntner P, Anderson A, Charleston J, et al. Chronic Renal Insufficiency Cohort (CRIC) Study InvestigatorsHypertension awareness, treatment, and control in adults with CKD: Results from the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis 2010; 55: 441-51.
[2]
Matsushita K, van der Velde M, Astor BC, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: A collaborative meta-analysis. Lancet 2010; 375: 2073-81.
[3]
Ninomiya T, Perkovic V, Turnbull F, et al. Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: Meta-analysis of randomised controlled trials. BMJ 2013; 347: f5680.
[4]
Jafar TH, Schmid CH, Landa M, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001; 135: 73-87.
[5]
Casas JP, Chua W, Loukogeorgakis S, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: Systematic review and meta-analysis. Lancet 2005; 366: 2026-33.
[6]
Strippoli GF, Bonifati C, Craig M, Navaneethan SD, Craig JC. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev 2006; 4: CD006257.
[7]
Balamuthusamy S, Srinivasan L, Verma M, et al. Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis. Am Heart J 2008; 155: 791-805.
[8]
Qin Y, Chen T, Chen Q, et al. The effect of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use on mortality in patients with chronic kidney disease: A meta-analysis of observational studies. Pharmacoepidemiol Drug Saf 2016; 25: 503-11.
[9]
Xie X, Liu Y, Perkovic V, et al. Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: A bayesian network meta-analysis of randomized clinical trials. Am J Kidney Dis 2016; 67: 728-41.
[10]
Clase CM, Barzilay J, Gao P, et al. Acute change in glomerular filtration rate with inhibition of the renin angiotensin system does not predict subsequent renal and cardiovascular outcomes. Kidney Int 2017; 91: 683-90.
[11]
Schmidt M, Mansfield KE, Bhaskaran K, et al. Serum creatinine elevation after renin-angiotensin system blockade and long term cardiorenal risks: Cohort study. BMJ 2017; 356: 791.
[12]
Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (theONTARGET study): A multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372: 547-53.
[13]
Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/ AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 2018; 71: e13-e115.
[14]
Ambrosioni E. Defining the role of zofenopril in the management of hypertension and ischemic heart disorders. Am J Cardiovasc Drugs 2007; 7: 17-24.
[15]
Cushman DW, Wang FL, Fung WC, Harvey CM, DeForrest JM. Differentiation of Angiotensin-Converting Enzyme (ACE) inhibitors by their selective inhibition of ACE in physiologically important target organs. Am J Hypertens 1989; 2: 294-306.
[16]
Subissi A, Evangelista S, Giachetti A. Preclinical profile of zofenopril: An angiotensin converting enzyme inhibitor with peculiar cardioprotective properties. Cardiovasc Drug Rev 1999; 17: 115-33.
[17]
Sun Y, Mendelsohn FA. Angiotensin converting enzyme inhibition in heart, kidney, and serum studied ex vivo after administration of zofenopril, captopril, and lisinopril. J Cardiovasc Pharmacol 1991; 18: 478-86.
[18]
Parati G, Omboni S, Malacco E. on behalf of the Study Group.Antihypertensive efficacy of zofenopril and hydrochlorothiazide combination on ambulatory blood pressure. Blood Press 2006; 15(Suppl. 1): 7-17.
[19]
Borghi C, Bacchelli S, Degli Esposti D. Long-term clinical experience with zofenopril. Expert Rev Cardiovasc Ther 2012; 10: 973-82.
[20]
Omboni S, Borghi C. Zofenopril and incidence of cough: A review of published and unpublished data Ther Clin Risk Manag . 2011; 7: 459-71.
[21]
Matarrese M, Salimbeni A, Turolla EA, et al. 11C-Radiosynthesis and preliminary human evaluation of the disposition of the ACE inhibitor [11C]zofenoprilat. Bioorg Med Chem 2004; 12: 603-11.
[22]
Cushman DW, Wang FL, Fung WC, et al. Comparisons in vitro, ex vivo, and in vivo of the actions of seven structurally diverse inhibitors of Angiotensin Converting Enzyme (ACE). Br J Clin Pharmacol 1989; 28(Suppl. 2): 115S-30S.
[23]
Altunoluk B, Soylemez H, Oguz F, Turkmen E, Fadillioglu E. An Angiotensin-converting enzyme inhibitor, zofenopril, prevents renal ischemia/reperfusion injury in rats. Ann Clin Lab Sci 2006; Summer 36: 326-32.
[24]
García-Estañ J, Ortiz MC, O’Valle F, et al. Effects of angiotensin-converting-enzyme inhibitors in combination with diuretics on blood pressure and renal injury in nitric oxide-deficiency-induced hypertension in rats. Clin Sci (Lond) 2006; 110: 227-33.
[25]
Singhvi SM, Foley JE, Willard DA, Morrison RA. Disposition of zofenopril calcium in healthy subjects. J Pharm Sci 1990; 79: 970-3.
[26]
Lowenthal DT, Somani P. Report on the pharmacokinetics of SQ 26,333-14C administered orally as 14C-zofenopril to patients with various degrees of renal impairment (Study 21,974-10). Unpublished data
[27]
Carville S, Wonderling D, Stevens P. Guideline Development Group Early identification and management of chronic kidney disease in adults: Summary of updated NICE guidance. BMJ 2014; 349: g4507.
[28]
Somani P, Luft FC. Report of the pharmacokinetics of 14C-SQ 26,333 after the oral administration of 14C-zofenopril calcium to patients on chronic peritoneal dialysis or haemodialysis (Study 21,974-15). Unpublished data.
[29]
Westendorp B, Schoemaker RG, van Gilst WH, van Veldhuisen DJ, Buikema H. Hydrochlorothiazide increases plasma or tissue angiotensin-converting enzyme-inhibitor drug levels in rats with myocardial infarction: Differential effects on lisinopril and zofenopril. Eur J Pharmacol 2005; 527: 141-9.
[32]
Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. N Engl J Med 1995; 332: 80-5.
[33]
Borghi C, Ambrosioni E. Survival of Myocardial Infarction Long-term Evaluation-2 Working Party. Double-blind comparison between zofenopril and lisinopril in patients with acute myocardial infarction: Results of the Survival of Myocardial Infarction Long-term Evaluation-2 (SMILE-2) study. Am Heart J 2003; 145: 80-7.
[34]
Borghi C, Ambrosioni E. Survival of Myocardial Infarction Long-term Evaluation Study Group Effects of zofenopril on myocardial ischemia in post-myocardial infarction patients with preserved left ventricular function: The Survival of Myocardial Infarction Long-term Evaluation (SMILE)-ISCHEMIA study. Am Heart J 2007; 153: 445.e7-445.e14.
[35]
Borghi C, Ambrosioni E, Novo S, Vinereanu D, Ambrosio G. G; SMILE-4 Working Party.Comparison between zofenopril and ramipril in combination with acetylsalicylic acid in patients with left ventricular systolic dysfunction after acute myocardial infarction: results of a randomized, double-blind, parallel-group, multicenter, European study (SMILE-4). Clin Cardiol 2012; 35: 416-23.
[36]
Borghi C, Cosentino ER, Rinaldi ER, Cicero AF. Effect of zofenopril and ramipril on cardiovascular mortality in patients with chronic heart failure. Am J Cardiol 2013; 112: 90-3.
[37]
Omboni S, Malacco E, Parati G. Zofenopril plus hydrochlorothiazide fixed combination in the treatment of hypertension and associated clinical conditions. Cardiovasc Ther 2009 Winter; 27: 275-88.
[38]
Zofenopril calcium and zofenopril calcium plus hydrochlorothiazide.Investigator’s Brochure. Version 8.0. September 10th, 2015.Unpublished data
[39]
Omboni S, Malacco E, Napoli C, et al. Efficacy of zofenopril vs. irbesartan in combination with a thiazide diuretic in hypertensive patients with multiple risk factors not controlled by a previous monotherapy: A review of the double-blind, randomized “Z” studies. Adv Ther 2017; 34: 784-98.
[40]
Borghi C, Omboni S, Reggiardo G, Bacchelli S, Degli Esposti D, Ambrosioni E. Cardioprotective role of zofenopril in patients with acute myocardial infarction: A pooled individual data analysis of four randomised, double-blind, controlled, prospective studies. Open Heart 2015; 2: e000220.
[41]
Comparison of once-daily zofenopril and enalapril in the treatment of essential hypertension in renal-imparied patients (Study 21,974-28). Unpublished data..
[42]
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
[43]
National Kidney Foundation.K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 2002; 39(2)(Suppl. 1): S1-S266.
[44]
Agabiti-Rosei E, Manolis A, Zava D, Omboni S. ZODIAC Study Group Zofenopril plus hydrochlorothiazide and irbesartan plus hydrochlorothiazide in previously treated and uncontrolled diabetic and non-diabetic essential hypertensive patients. Adv Ther 2014; 31: 217-33.
[45]
Malacco E, Omboni S, Parati G. Blood pressure response to zofenopril or irbesartan each combined with hydrochlorothiazide in high-risk hypertensives uncontrolled by monotherapy: A randomized, double-blind, controlled, parallel group, noninferiority Trial. Int J Hypertens 2015; 2015: 139465.
[46]
Modesti PA, Omboni S, Taddei S, et al. Zofenopril or irbesartan plus hydrochlorothiazide in elderly patients with isolated systolic hypertension untreated or uncontrolled by previous treatment: a double-blind, randomized study. J Hypertens 2016; 34: 576-87.
[47]
Williams B, Mancia G, Spiering W, et al. ESC Scientific Document Group 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018; 39: 3021-104.
67
11
3
2